Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00538720 · ClinicalTrials.gov registry record · Phase 1

Effects of Vitamin D Replacement in Patients With Primary Hyperparathyroidism (PHPT)

A Phase 1 study of Hyperparathyroidism, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
Phase 1
Development phase
22
Enrollment target
1
Study location

NCT00538720: Completed Phase 1 study of Hyperparathyroidism, sponsored by M.D. Anderson Cancer Center.

NCT00538720 is a Phase 1 study of Hyperparathyroidism that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 22 participants, below the 131-participant average among 7 other Hyperparathyroidism trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00538720, a Phase 1 study of Hyperparathyroidism, has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
Phase 1
Development phase
22 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical research study is to learn how the standard practice of giving Vitamin D supplements to patients with a Vitamin D deficiency may affect the size of the parathyroid glands in patients with PHPT and a Vitamin D deficiency.

Primary Outcome

Size of individual gland recorded while only the gland with maximum size at baseline included for analysis of primary endpoint. With sample size of 22, a two-sided 95% confidence interval for mean changes in size of parathyroid glands will extend 2.09 from observed mean, assuming that standard deviation is known to be 5 and confidence interval is based on the z statistic. Parameters for parathyroid glands compared pre- and post-replacement on an individual, gland-by-gland basis.

Conditions Studied

Interventions

  • DRUG Vitamin D
  • DEVICE Four-dimensional computed tomography (4DCT)

Study Locations (1)

Texas

  • University of Texas MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2007-10
Est. Completion 2018-05-30
Phase Phase 1
M.D. Anderson Cancer Center

2,692 total trials

What the finished NCT00538720 record still lists

NCT00538720 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 131-participant average among 7 other Hyperparathyroidism trials with a reported enrollment target (83% lower).

The record links to 1 condition, with Hyperparathyroidism appearing as the primary indexed condition, and to 2 interventions - of which Vitamin D is the first listed.

NCT00538720 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT00538720 about?

NCT00538720 is a clinical study titled "Effects of Vitamin D Replacement in Patients With Primary Hyperparathyroidism (PHPT)". The goal of this clinical research study is to learn how the standard practice of giving Vitamin D supplements to patients with a Vitamin D deficiency may affect the size of the parathyroid glands in patients with PHPT and a Vitamin D deficiency.

What is the current status of trial NCT00538720?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2007-10. Estimated completion is 2018-05-30.

What conditions does trial NCT00538720 study?

This clinical trial studies the following conditions: Hyperparathyroidism.

What interventions are being tested in trial NCT00538720?

The interventions under investigation include: Vitamin D (DRUG), Four-dimensional computed tomography (4DCT) (DEVICE).

Who is sponsoring clinical trial NCT00538720?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00538720 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hyperparathyroidism

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02508038 · 22 participants · Phase 1

    Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

  • NCT03099356 · 22 participants · Phase 2

    Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

  • NCT03676647 · 22 participants

    Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules

  • NCT04569591 · 22 participants · NA

    DDAVP for Pituitary Adenoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00538720, the US trial registry maintained by the National Library of Medicine. NCT00538720 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.